247 related articles for article (PubMed ID: 17021258)
1. Nicotinamide reverses neurological and neurovascular deficits in streptozotocin diabetic rats.
Stevens MJ; Li F; Drel VR; Abatan OI; Kim H; Burnett D; Larkin D; Obrosova IG
J Pharmacol Exp Ther; 2007 Jan; 320(1):458-64. PubMed ID: 17021258
[TBL] [Abstract][Full Text] [Related]
2. Functional and biochemical evidence indicating beneficial effect of Melatonin and Nicotinamide alone and in combination in experimental diabetic neuropathy.
Negi G; Kumar A; Kaundal RK; Gulati A; Sharma SS
Neuropharmacology; 2010 Mar; 58(3):585-92. PubMed ID: 20005237
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy.
Li F; Szabó C; Pacher P; Southan GJ; Abatan OI; Charniauskaya T; Stevens MJ; Obrosova IG
Diabetologia; 2004 Apr; 47(4):710-7. PubMed ID: 15298348
[TBL] [Abstract][Full Text] [Related]
4. Low-dose poly(ADP-ribose) polymerase inhibitor-containing combination therapies reverse early peripheral diabetic neuropathy.
Li F; Drel VR; Szabó C; Stevens MJ; Obrosova IG
Diabetes; 2005 May; 54(5):1514-22. PubMed ID: 15855340
[TBL] [Abstract][Full Text] [Related]
5. Depletion of taurine in experimental diabetic neuropathy: implications for nerve metabolic, vascular, and functional deficits.
Pop-Busui R; Sullivan KA; Van Huysen C; Bayer L; Cao X; Towns R; Stevens MJ
Exp Neurol; 2001 Apr; 168(2):259-72. PubMed ID: 11259114
[TBL] [Abstract][Full Text] [Related]
6. Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy.
Obrosova IG; Li F; Abatan OI; Forsell MA; Komjáti K; Pacher P; Szabó C; Stevens MJ
Diabetes; 2004 Mar; 53(3):711-20. PubMed ID: 14988256
[TBL] [Abstract][Full Text] [Related]
7. Poly(ADP-ribose) polymerase inhibition alleviates experimental diabetic sensory neuropathy.
Ilnytska O; Lyzogubov VV; Stevens MJ; Drel VR; Mashtalir N; Pacher P; Yorek MA; Obrosova IG
Diabetes; 2006 Jun; 55(6):1686-94. PubMed ID: 16731831
[TBL] [Abstract][Full Text] [Related]
8. Oxidative-nitrosative stress and poly(ADP-ribose) polymerase (PARP) activation in experimental diabetic neuropathy: the relation is revisited.
Obrosova IG; Drel VR; Pacher P; Ilnytska O; Wang ZQ; Stevens MJ; Yorek MA
Diabetes; 2005 Dec; 54(12):3435-41. PubMed ID: 16306359
[TBL] [Abstract][Full Text] [Related]
9. Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications.
Obrosova IG; Pacher P; Szabó C; Zsengeller Z; Hirooka H; Stevens MJ; Yorek MA
Diabetes; 2005 Jan; 54(1):234-42. PubMed ID: 15616034
[TBL] [Abstract][Full Text] [Related]
10. Role of nitrosative stress in early neuropathy and vascular dysfunction in streptozotocin-diabetic rats.
Obrosova IG; Drel VR; Oltman CL; Mashtalir N; Tibrewala J; Groves JT; Yorek MA
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1645-55. PubMed ID: 17911342
[TBL] [Abstract][Full Text] [Related]
11. Taurine counteracts oxidative stress and nerve growth factor deficit in early experimental diabetic neuropathy.
Obrosova IG; Fathallah L; Stevens MJ
Exp Neurol; 2001 Nov; 172(1):211-9. PubMed ID: 11681853
[TBL] [Abstract][Full Text] [Related]
12. Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic and streptozotocin-diabetic rats.
Cameron NE; Cotter MA; Archibald V; Dines KC; Maxfield EK
Diabetologia; 1994 May; 37(5):449-59. PubMed ID: 8056181
[TBL] [Abstract][Full Text] [Related]
13. Poly(ADP-ribosyl)ation enhancement in brain cell nuclei is associated with diabetic neuropathy.
Kuchmerovska T; Shymanskyy I; Donchenko G; Kuchmerovskyy M; Pakirbaieva L; Klimenko A
J Diabetes Complications; 2004; 18(4):198-204. PubMed ID: 15207836
[TBL] [Abstract][Full Text] [Related]
14. PARP inhibition alleviates diabetes-induced systemic oxidative stress and neural tissue 4-hydroxynonenal adduct accumulation: correlation with peripheral nerve function.
Lupachyk S; Shevalye H; Maksimchyk Y; Drel VR; Obrosova IG
Free Radic Biol Med; 2011 May; 50(10):1400-9. PubMed ID: 21300148
[TBL] [Abstract][Full Text] [Related]
15. New therapeutic and biomarker discovery for peripheral diabetic neuropathy: PARP inhibitor, nitrotyrosine, and tumor necrosis factor-{alpha}.
Drel VR; Lupachyk S; Shevalye H; Vareniuk I; Xu W; Zhang J; Delamere NA; Shahidullah M; Slusher B; Obrosova IG
Endocrinology; 2010 Jun; 151(6):2547-55. PubMed ID: 20357221
[TBL] [Abstract][Full Text] [Related]
16. Effects of the protein kinase C beta inhibitor LY333531 on neural and vascular function in rats with streptozotocin-induced diabetes.
Cotter MA; Jack AM; Cameron NE
Clin Sci (Lond); 2002 Sep; 103(3):311-21. PubMed ID: 12193157
[TBL] [Abstract][Full Text] [Related]
17. Baicalein alleviates diabetic peripheral neuropathy through inhibition of oxidative-nitrosative stress and p38 MAPK activation.
Stavniichuk R; Drel VR; Shevalye H; Maksimchyk Y; Kuchmerovska TM; Nadler JL; Obrosova IG
Exp Neurol; 2011 Jul; 230(1):106-13. PubMed ID: 21515260
[TBL] [Abstract][Full Text] [Related]
18. Treatment with the xanthine oxidase inhibitor, allopurinol, improves nerve and vascular function in diabetic rats.
Inkster ME; Cotter MA; Cameron NE
Eur J Pharmacol; 2007 Apr; 561(1-3):63-71. PubMed ID: 17291486
[TBL] [Abstract][Full Text] [Related]
19. A peroxynitrite decomposition catalyst counteracts sensory neuropathy in streptozotocin-diabetic mice.
Drel VR; Pacher P; Vareniuk I; Pavlov I; Ilnytska O; Lyzogubov VV; Tibrewala J; Groves JT; Obrosova IG
Eur J Pharmacol; 2007 Aug; 569(1-2):48-58. PubMed ID: 17644085
[TBL] [Abstract][Full Text] [Related]
20. Poly(Adenosine 5'-diphosphate-ribose) polymerase inhibition counteracts multiple manifestations of experimental type 1 diabetic nephropathy.
Drel VR; Xu W; Zhang J; Pavlov IA; Shevalye H; Slusher B; Obrosova IG
Endocrinology; 2009 Dec; 150(12):5273-83. PubMed ID: 19854869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
